Please try another search
For the nine months ended 30 September 2018, Argos Therapeutics Inc revenues increased from $228K to $7.2M. Net loss decreased 65% to $13.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Impairment loss on property and equipmen decrease from $27.2M (expense) to $0K, Restructuring costs decrease from $6M (expense) to $0K.
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 1.25 | 0.05 | 5.93 | 1.67 |
Gross Profit | ||||
Operating Income | -4.81 | -6.37 | -2.11 | -1.74 |
Net Income | -5 | -6.48 | -2.11 | -1.89 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 10.88 | 16.79 | 22.16 | 20.78 |
Total Liabilities | 23.45 | 24.92 | 25.34 | 30.01 |
Total Equity | -12.57 | -8.14 | -3.18 | -9.23 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -14.65 | -10.78 | -5.45 | -35.42 |
Cash From Investing Activities | 0.63 | 0.61 | 0.31 | 0.32 |
Cash From Financing Activities | 6.77 | 7.11 | 6.98 | -2.68 |
Net Change in Cash | -7.25 | -3.06 | 1.83 | -37.78 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review